Dr. Rachel Meyers, Ph.D. serves as Senior Vice President of Research and Member of Scientific Advisory Board at Alnylam Pharmaceuticals, Inc. and served as its Vice President of Research and RLD. At Alnylam, Dr. Meyers oversees the RLD and immunology groups and plays a key role in the development of Alnylam's RNAi therapeutic programs. She joined Alnylam in April of 2003 as Associate Director of Research, after having served as a Senior Scientist at Millennium Pharmaceuticals from 1999 to 2003. At Millennium Pharmaceuticals, she was involved in target advancement and the identification, bioinformatic analysis, cloning and functional analysis of novel targets for small molecule drug discovery, antibody development and diagnostic purposes. She serves as Scientific Advisory Board Member at Editas Medicine Inc. Dr. Meyers is a member of the advisory board for the MS program in Biotechnology at Brandeis University. Dr. Meyers holds a degree in Biochemistry from Brandeis University and a Ph.D. in Biology from MIT and she completed her post-doctoral training at Harvard Medical School.

 Biotechnology